Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.55U.U.TO 0.27SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.3NESN-SIX 0MCK 27.62
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Jan 12, 2005
If you look at what has happened to the pharnaceuticals over the last 2 years, generally the big ethical drug companies have been very poor performers. Growth rates have dropped to low single digits. Prefers bio-tech or bio-pharmaceuticals that have growth.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$26.03

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 05, 2005
Has been hurt by the Cox-2 inhibitor problem which is in their Celbrex and Bextra. Pharmaceutical stocks in general have all been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$26.27

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 24, 2004
(A Top Pick Oct 26/04. Down 8%.) Model price is $39. Totally mispriced. Should be a portion of everybody's portfolio. Looking out a year, you should make good money off it.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 17, 2004
There was a negative call on one of their drugs which affected the stock price dramatically. This will mean a lot more testing and a lot more money. Have other products in their stable they can go with.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 17, 2004
When a stock gets hit with very negative news, there tends to be an overreaction, so it's best to put in a very lowball bid. If you get it there, fine, if not, you'll probably get a second chance.
Photo of David DremanDavid Dreman
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Dec 17, 2004
Wait and see how things shake out. Only one day on the news and there's lots of interpretations on what it means.
Photo of Bill MacLachlanBill MacLachlan
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 16, 2004
Biggest problem with the drugs has to do with the litigation problems in the US. George Bush has asked Congress to drastically reduce the awards. If successful, it will be a huge win for drug companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$28.98

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 16, 2004
Quality at a discount. There will be a lot of opportunity for upward surprises and multiple expansion. Trades at 11.7 X next year's earnings which is a 22% discount to its peer group. Have a wide and deep pipeline.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.98

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 10, 2004
Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.09

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 09, 2004
Everyone is scared to death of the pharmaceuticals because of litigation risks. Have got terrific drugs, but there's going to be blood ankle deep on the floor because of Vioxx.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$27.37

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 30, 2004
Of all the drug companies put together, this company has the strongest pipe line. This is a mispriced asset. When you lok at the earnings, the balance sheet and where interest rates are, it's worth $50.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.23

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 29, 2004
Merck had to pull their rheumatoid arthritis drug. Pfizer's drug is somewhat similar which caused investors to sell. FDA says it is a safe drug, so the stock is at a good price.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$27.33

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2004
A very good company, but the recent problems with Bayer's similar drugs has him scared.
Photo of Neil WickhamNeil Wickham
No
Unlock Rating
$26.90

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 18, 2004
Offers reasonable opportunity here, but could be a long go before there are signs of recovery. Cheap. Long term concern is possible pricing controls.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$27.77

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 11, 2004
The big block buster drugs are starting to face generic competition. Very cheap, but the market is worried about nothing being on the horizon for 2005/2006. Under $30 is a good price. Be willing to sit and wait. A great story.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$27.15

Stock price when the opinion was issued

$28.46

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 691 to 705 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.86$313.26
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.545$53.455

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.55$96.08
U.U.TO 0.27$20.69
SII.TO 5.37$192.56
IPCO.TO -0.2$35.02

Popular Articles

Latest Sell Signals

RKLB -1.06$67.22
INTC 0.41$87.67
MSFT 3.81$491.12
WSP.TO -2.98$189.3
CLS.TO 14.99$422.35

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like